Stockscreener 앱 받기
40.44
1.71%
0.68
시장 영업 전:
40.10
-0.34
-0.84%
Cogent Biosciences Inc 주식(COGT)의 최신 뉴스
BlackRock (COGT holder) discloses 8.0% ownership in Cogent Biosciences common stock - Stock Titan
Cogent Biosciences Inc (COGT) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Cogent Biosciences Inc (COGT) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
COGT|Cogent Biosciences Inc|Price:40.450|Chg%:+0.690 - TradingKey
COGT|Cogent Biosciences Inc|Price:39.760|Chg%:-0.480 - TradingKey
Cogent Biosciences Inc (COGT) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Cogent Biosciences Inc (COGT) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
(COGT) Movement Within Algorithmic Entry Frameworks - Stock Traders Daily
COGT6232219 Bond Risk Profile - TradingView
COGT6232219 Bond Coupon Profile — Rate & Payments - TradingView
COGT6232219 Bond Profile — Key Metrics - TradingView
Cogent Bioscience (COGT) Files New Drug Application For Bezuclastinib - Yahoo Finance
Price to sales forward of Cogent Biosciences, Inc. – NASDAQ:COGT - TradingView
Enterprise value to EBITDA forward of Cogent Biosciences, Inc. – NASDAQ:COGT - TradingView
Cogent Biosciences (COGT) Files FDA Application As Bezuclastinib Hype Meets A Pricey Valuation - Sahm
Price to book forward of Cogent Biosciences, Inc. – NASDAQ:COGT - TradingView
Is Bezuclastinib’s FDA Filing And Disease-Modifying Data Altering The Investment Case For Cogent Biosciences (COGT)? - Sahm
Cogent Biosciences (COGT) director takes options in lieu of cash - Stock Titan
Cogent Biosciences (COGT) Edges Higher, Tests Key Resistance Amid Sector TailwindsFlat Correction - dars.gov.et
Enterprise value to revenue forward of Cogent Biosciences, Inc. – NASDAQ:COGT - TradingView
3 Reasons Cogent Biosciences (COGT) Looks Pricey After Its FDA Filing - Sahm
COGTCogent Biosciences Inc Forecast, Target Price - Finviz
How (COGT) Movements Inform Risk Allocation Models - Stock Traders Daily
Cogent Biosciences Announces Submission of New Drug Application for Bezuclastinib in Advanced Systemic Mastocytosis - Investing News Network
Cogent Biosciences Submits US FDA New Drug Application for Potential Mast Cell Disease Treatment - marketscreener.com
Cogent Biosciences (COGT) Submits NDA to FDA for Bezuclastinib - GuruFocus
Cogent Biosciences Announces Submission of New Drug Application (NDA) for Bezuclastinib in Advanced Systemic Mastocytosis (AdvSM) - The Manila Times
Cogent Biosciences Announces Submission of New Drug - GlobeNewswire
Why Cogent Biosciences (COGT) Is Up 6.7% After Russell Index Removal Reshapes Its Investor Base - simplywall.st
Cogent Biosciences stock retreats after recent gains as bullish momentum consolidates - Traders Union
Cogent Biosciences stock edges lower with sideways action after Elevation Summit event - Traders Union
Cogent Biosciences, Inc.(NasdaqGS: COGT) dropped from Russell 2000 Value Benchmark - marketscreener.com
Cogent Biosciences, Inc.(NasdaqGS:COGT) dropped from Russell Microcap Value Benchmark Index - marketscreener.com
Cogent Biosciences, Inc.(NasdaqGS:COGT) dropped from Russell Microcap Growth Benchmark Index - marketscreener.com
Cogent Biosciences, Inc. Actuals & Estimates (NASDAQ:COGT) - TradingView
Cogent Biosciences, Inc.(NasdaqGS:COGT) dropped from Russell 3000E Growth Benchmark - marketscreener.com
Cogent Biosciences, Inc.(NasdaqGS: COGT) dropped from Russell Microcap Index - marketscreener.com
Cogent Biosciences, Inc.(NasdaqGS: COGT) dropped from Russell 3000 Value Benchmark - marketscreener.com
Cogent Biosciences | 4: Statement of changes in beneficial ownership of securities-Director Ros Matthew - Moomoo
Cogent Biosciences | 4: Statement of changes in beneficial ownership of securities-Director Shegog Todd - Moomoo
Cogent Biosciences | 4: Statement of changes in beneficial ownership of securities-Officer Robbins Andrew R - Moomoo
COGT Forecast — Price Target — Prediction for 2027 - TradingView
Cogent (COGT) Presents Preclinical Data for Novel JAK2 Inhibitor CGT1145 at 2026 EHA Congress - Insider Monkey
Is Cogent Biosciences (COGT) ’s New Cancer Drug 100 Times More Precise Than What’s Already on the Market? - Yahoo Finance
New Bezuclastinib and JAK2 Data Could Be A Game Changer For Cogent Biosciences (COGT) - Sahm
Trading Systems Reacting to (COGT) Volatility - Stock Traders Daily
H.C. Wainwright Sticks to Its Buy Rating for Cogent Biosciences (COGT) - The Globe and Mail
H.C. Wainwright Maintains Cogent Biosciences(COGT.US) With Buy Rating, Maintains Target Price $55 - Moomoo
Cogent Biosciences Inc (COGT) Institutional Confidence - TradingKey
Cogent Biosciences Inc (COGT) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Cogent Biosciences Inc (COGT) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Cogent Biosciences Inc (COGT) Valuation: PE, PB & Fair Value Analysis - TradingKey
Cogent Biosciences (COGT) Gains 1.92% as Biotech Sector Momentum BuildsLeveraged ETF Flow - Město Břeclav
Cogent Biosciences Inc (COGT) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Stifel reiterates Cogent stock Buy rating after trial data - Investing.com UK
Stifel reiterates Cogent stock Buy rating after trial data By Investing.com - Investing.com India
1.97%
0.83%
자본화:
|
볼륨(24시간):